| Literature DB >> 11257398 |
T M Foy1, J Bannink, R A Sutherland, P D McNeill, G G Moulton, J Smith, M A Cheever, K Grabstein.
Abstract
The present study utilizes an in vivo murine tumor expressing human Her-2/neu to evaluate potential Her-2/neu vaccines consisting of either full length or various subunits of Her-2/neu delivered in either protein or plasmid DNA form. Our results demonstrate that protective immunity against Her-2/neu-expressing tumor challenge can be achieved by vaccination with plasmid DNA encoding either full length or subunits of Her-2/neu. Partial protective immunity was also observed following vaccination with the intracellular domain (ICD), but not extracellular domain (ECD), protein subunit of Her-2/neu. The mechanism of protection elicited by plasmid DNA vaccination appeared to be exclusively CD4 dependent, whereas the protection observed with ICD protein vaccination required both CD4 and CD8 T cells.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11257398 DOI： 10.1016/s0264-410x(00)00493-x
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641